Welcome to our dedicated page for Beigene news (Ticker: ONC), a resource for investors and traders seeking the latest updates and insights on Beigene stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Beigene's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Beigene's position in the market.
BeiGene (NASDAQ: ONC) has scheduled the release of its fourth quarter and full year 2024 financial results for Thursday, February 27, 2025, before market open. The company, which plans to change its name to BeOne Medicines, will host a live webcast with management at 8:00 a.m. ET following the financial release.
Investors can access the webcast through BeiGene's investor relations websites. Participants are advised to register 15 minutes before the scheduled start time to ensure proper connection. An archived version of the webcast will be made available on the company's website afterward.
BeiGene (NASDAQ: ONC) has appointed Giancarlo Benelli as Senior Vice President and Head of Europe, effective January 1st. The company, which plans to change its name to BeOne Medicines , aims to strengthen its European presence through this strategic appointment. Benelli brings over 20 years of pharmaceutical industry experience from positions at Novartis and AstraZeneca, most recently serving as Vice President and Head Radioligand Therapy International Markets at Novartis.
Benelli will lead BeiGene's European operations from Basel, Switzerland, overseeing more than 800 colleagues across the region. His previous experience includes serving as General Manager at Advanced Accelerators Applications, where he managed post-acquisition restructuring and successful product launches. He holds a Medical Doctorate and Post Graduate Diploma in Thoracic Surgery from the University of Genoa, and a Diploma in Health Economics from the University of York.
FAQ
What is the current stock price of Beigene (ONC)?
What is the market cap of Beigene (ONC)?
